Kristine M Eilers

Author PubWeight™ 10.92^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30.	J Clin Oncol	2004	2.92
2	Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer.	J Clin Oncol	2003	2.07
3	C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial.	Cancer	2008	1.92
4	C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results.	Urol Oncol	2010	1.02
5	Docetaxel (taxotere) in the treatment of prostate cancer.	Expert Rev Anticancer Ther	2003	0.97
6	A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy.	Anticancer Drugs	2010	0.84
7	Rationale for the development and current status of calcitriol in androgen-independent prostate cancer.	World J Urol	2005	0.78
8	Prostate-specific antigen decline after gonadotropin-releasing hormone antagonist withdrawal in androgen-independent prostate cancer.	Urology	2005	0.77
9	Quality of life and pain relief during treatment with calcitriol and docetaxel in symptomatic metastatic androgen-independent prostate carcinoma.	Cancer	2004	0.75